TCBIO

Value Q3, 24Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25 TTM Total revenue 344.87 M36.14 M263.48 M292.46 M328.35 M316.48 M 1.2 B Gross profit 334.87 M18.14 M246.48 M277.46 M316.35 M305.48 M 1.15 B Operating expenses -117.72 M55.39 M66.91 M56.19 M59.71 M54.15 M 236.96 M Selling/general/admin expenses 62.34 M55.57 M67.23 M58.78 M60.55 M56.09 M 242.65 M Research & development —————— — Operating income 452.6 M-37.25 M179.57 M221.28 M256.64 M251.33 M 908.82 M Non-Operating Income, Total 173.71 M-5.59 M2.05 M-166 K00 1.89 M Interest expense, net of interest capitalized 226.22 M257.96 M199.5 M189.62 M189.38 M191.25 M 769.75 M Non-Operating Income, excl. Interest Expenses -52.51 M-263.54 M-197.45 M-189.78 M-189.38 M-191.25 M -767.86 M Unusual income/expense —————— — Pretax income -79.99 M93.52 M60.46 M102.19 M137.78 M132.28 M 432.71 M Equity in earnings —————— — Taxes -18.67 M22.5 M13.41 M24.86 M32.57 M31.63 M 102.47 M Non-controlling/minority interest —————— — After tax other income/expense —————— — Net income before discontinued operations -61.32 M71.02 M47.05 M77.33 M105.21 M100.66 M 330.24 M Discontinued operations —————— — Net income -61.32 M71.02 M47.05 M77.33 M105.21 M100.66 M 330.24 M Dilution adjustment 131.26 M-131.26 M0000 0 Preferred dividends 4.31 M4.31 M4.31 M4.31 M4.31 M4.31 M 17.25 M Diluted net income available to common stockholders 65.63 M-64.55 M42.73 M73.02 M100.9 M96.35 M 312.99 M Basic earnings per share (Basic EPS) -1.421.450.931.592.212.13 6.86 Diluted earnings per share (Diluted EPS) -1.41.430.921.572.172.11 6.77 Average basic shares outstanding 46.67 M46.56 M46.12 M45.96 M45.87 M45.64 M 183.59 M Diluted shares outstanding 47.05 M46.99 M46.62 M46.4 M46.35 M46.13 M 185.5 M EBITDA 466.68 M-21.94 M188.79 M235.73 M269.26 M267.21 M 960.99 M EBIT 452.6 M-37.25 M179.57 M221.28 M256.64 M251.33 M 908.82 M Cost of revenue 10 M18 M17 M15 M12 M11 M 55 M Other cost of goods sold —————— — Depreciation & amortization (cash flow) 14.08 M15.31 M9.22 M14.45 M12.62 M15.88 M 52.17 M